Characteristic of Korea SW Process Certification Model

Abstract

As representative international software process models, ISO/IEC 15504(Software Process Improvement and Capability determination) and CMMI(Capability Maturity Model Integration) can be considered. In this paper we present the Korea software process certification mode (K-model) that can be easily applied on small and medium sized business to process improvement and certification in Korea. This study also compares the practices of K-model with practices of CMMI and ISO/IEC 15504. We expect that the small and light nature of Kmodel will improve the software process for Korea enterprises.

TRPV1 antagonist with high analgesic efficacy: 2-Thio pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides

“…The transient receptor potential V1 (TRPV1) receptor is a molecular integrator of nociceptive stimuli predominantly expressed on sensory neurons. 1 It is activated by multiple endogenous agonists including protons, 2 noxious heat, 3 and inflammatory lipid mediators 4,5 as well as by natural products such as capsaicin (CAP) 6 and resiniferatoxin (RTX). 7 The pharmacological blockade of TRPV1, by inhibiting the transmission of nociceptive signaling from the periphery to the CNS, provides a promising strategy for the development of novel analgesics.…”

2-Aryl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as highly potent TRPV1 antagonists

“…1 Located predominantly in C-fiber sensory afferent neurons, TRPV1 is a nociceptor which integrates stimuli from exogenous compounds such as capsaicin, endogenous endovanilloids, heat and acidity. [2][3][4][5][6][7] TRPV1 is further co-regulated by the signaling milieu of the cell, as reflected in the activity of kinases such as protein kinase C, protein kinase A, or the level of phosphatidylinositol-4,5-bisphosphate. Development of antagonists represents the leading therapeutic strategy, while defunctionalization/desensitization subsequent to agonist stimulation also holds promise.…”